There is plenty of discussion that can be had when referring to the condition known as glioblastoma. Viewed as the very condition that took the life of Senator Edward Kennedy a few years ago, it is seen as the most aggressive and common condition in the brain. As a result, therapies are built and drugs are tested in order to see which of these can yield the greatest of the results. After reading about the inclusion of HSPPC-96, I think that there is even more discussion that can be made by Stuart Millheiser and others.
News-Medical posted an article that spoke about an experimental vaccine that could be used in order to help those who have this condition. It would entail a degree of tumor tissue, which is needed in order to make it impactful. As the article would go on to state, patients saw increased levels of survival in comparison to what they might have had with only standard methods of care. There is quite a bit to talk about when it comes to the phase 2 trial tied to this vaccine.
What is it that makes glioblastoma, in general, one of the most serious conditions that be associated with the likes of ALS? The article went into detail about this and it seems as though these types of tumors are able to accelerate quickly, meaning that treatment options are rather limited. There is a common procedure: typical surgery followed by bouts of chemo and radiation. The results are not always ones that will last in the long run, though, meaning that stories like these have the attention of names such as Stuart Millheiser.
The phase 2 trial was done and it was conducted with a group of 41 adult patients, each of them possessing tumors between the years of 2007 and 2011. Each patient was given around six doses of HSPPC-96, the vaccine with the tumor tissue, as mentioned earlier. Following this implementation, the report said that 90 percent of people in the group were still alive after six months and 30 percent of them were still living after a year. To say that there is potential here would be an understatement, as I'm sure Stu Millheiser can attest to.
Treatment is one of those ideas linked to glioblastoma research that is constantly being worked on. It seems as though treatment in general is one of the broadest areas to consider as well and the fact that there are so many details to consider speaks volumes. Stem cells have been put to use in the past, so the tissue from tumors should be utilized if there are incentives to consider. To me, this goes to show that the degree of potential will prove to be one of the greatest.
News-Medical posted an article that spoke about an experimental vaccine that could be used in order to help those who have this condition. It would entail a degree of tumor tissue, which is needed in order to make it impactful. As the article would go on to state, patients saw increased levels of survival in comparison to what they might have had with only standard methods of care. There is quite a bit to talk about when it comes to the phase 2 trial tied to this vaccine.
What is it that makes glioblastoma, in general, one of the most serious conditions that be associated with the likes of ALS? The article went into detail about this and it seems as though these types of tumors are able to accelerate quickly, meaning that treatment options are rather limited. There is a common procedure: typical surgery followed by bouts of chemo and radiation. The results are not always ones that will last in the long run, though, meaning that stories like these have the attention of names such as Stuart Millheiser.
The phase 2 trial was done and it was conducted with a group of 41 adult patients, each of them possessing tumors between the years of 2007 and 2011. Each patient was given around six doses of HSPPC-96, the vaccine with the tumor tissue, as mentioned earlier. Following this implementation, the report said that 90 percent of people in the group were still alive after six months and 30 percent of them were still living after a year. To say that there is potential here would be an understatement, as I'm sure Stu Millheiser can attest to.
Treatment is one of those ideas linked to glioblastoma research that is constantly being worked on. It seems as though treatment in general is one of the broadest areas to consider as well and the fact that there are so many details to consider speaks volumes. Stem cells have been put to use in the past, so the tissue from tumors should be utilized if there are incentives to consider. To me, this goes to show that the degree of potential will prove to be one of the greatest.
About the Author:
For additional information about ALS and Stu Millheiser, overall, contact Stuart Millheiser now.
